News

FDA Clears Technology to Distinguish between Bacterial and Viral Infections

FDA grants 510(k) clearance for use of the MeMed BV® test to help distinguish between bacterial and viral infections

Brought to you byMeMed
| 3 min read
Image of blood in a vial being sent for testing
Register for free to listen to this article
Listen with Speechify
0:00
3:00

HAIFA, ISRAEL, BOSTON, MA — MeMed, a leader in the emerging field of advanced host-response technologies, announces that the U.S. Food and Drug Administration (FDA) has granted 510(k) clearance for use of the MeMed BV® test on the point-of-need platform MeMed Key® to help healthcare providers distinguish between bacterial and viral infections. The technology has been cleared for both children and adults.

Bacterial and viral infections are often clinically indistinguishable, leading to the prescription of antibiotics for the treatment of viral infections, for which they are ineffective. Antibiotic misuse drives the emergence of antimicrobial resistance (AMR), one of the biggest healthcare challenges of our time.

To continue reading this article, sign up for FREE
Today's Clinical Lab Logo
Membership is FREE and provides you with instant access to eNewsletters, digital publications, article archives, and more.
Unlock for FREE
Add Today's Clinical Lab as a preferred source on Google

Add Today's Clinical Lab as a preferred Google source to see more of our trusted coverage.

Related Topics